Ms. Emily Levy has over 27 years of business experience in biotechnology, with a focus on new product assessment, strategy and business development. Ms. Levy currently is Principal at Synergy Partners and recently served as the head of Fresenius Medical Care Ventures, which was established to invest in start-ups and early-stage companies in the healthcare sector.
Ms. Levy has also held management roles with the Diagnostics Division of Abbott Laboratories and Genzyme Corporation. While at Genzyme, she managed the early development of Ceredase for the treatment of Gaucher’s Disease and participated in the successful raising of the R&D Limited Partnership to fund the drug’s development. At Abbott, she was responsible for global business unit product management for immunoassay, CNS diagnostics, high-volume automation and data management products.
Since 1992, Levy has been consulting to pharmaceutical and biotechnology companies, venture capital firms and academic institutions. She has played an active role as an investor for a corporate life science venture fund of a healthcare system. In these roles, she has been involved in the due diligence, start up and growth of new ventures and corporate product development programs in clinical diagnostics and personalized medicine, new research tools, stem cells and new biologics and pharmaceuticals.
She served on the Board of Directors and as an Officer of HBS Health, a network of Harvard Business School alumni in healthcare, and was a board member of Mitomics, Inc., which focuses on the commercialization of novel molecular tests based on the mitochondrial genome. Levy currently serves on the board of the Association for Frontotemporal Degeneration and she co-founded the Boston area support group for caregivers of patients with these disorders. She holds an MBA from the Harvard Business School and a BA in chemistry from Swarthmore College.
